| Germ cell tumors of the ovary D Pectasides, E Pectasides, D Kassanos Cancer treatment reviews 34 (5), 427-441, 2008 | 307 | 2008 |
| Granulosa cell tumor of the ovary D Pectasides, E Pectasides, A Psyrri Cancer treatment reviews 34 (1), 1-12, 2008 | 298 | 2008 |
| Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma E Pectasides, MD Stachler, S Derks, Y Liu, S Maron, M Islam, L Alpert, ... Cancer discovery 8 (1), 37-48, 2018 | 275 | 2018 |
| Fallopian tube carcinoma: a review D Pectasides, E Pectasides, T Economopoulos The Oncologist 11 (8), 902-912, 2006 | 250 | 2006 |
| Activation of Wnt signaling pathway by human papillomavirus E6 and E7 oncogenes in HPV16-positive oropharyngeal squamous carcinoma cells T Rampias, E Boutati, E Pectasides, C Sasaki, P Kountourakis, ... Molecular Cancer Research 8 (3), 433-443, 2010 | 184 | 2010 |
| Chemotherapy for recurrent cervical cancer D Pectasides, K Kamposioras, G Papaxoinis, E Pectasides Cancer treatment reviews 34 (7), 603-613, 2008 | 154 | 2008 |
| Circulating tumor DNA in advanced solid tumors: clinical relevance and future directions ML Cheng, E Pectasides, GJ Hanna, HA Parsons, AD Choudhury, ... CA: a cancer journal for clinicians 71 (2), 176-190, 2021 | 139 | 2021 |
| Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma J Kim, C Fox, S Peng, M Pusung, E Pectasides, E Matthee, YS Hong, ... The Journal of clinical investigation 124 (12), 5145-5158, 2014 | 123 | 2014 |
| Sequencing treatment in BRAFV600 mutant melanoma: anti-PD-1 before and after BRAF inhibition DB Johnson, E Pectasides, E Feld, F Ye, S Zhao, R Johnpulle, R Merritt, ... Journal of immunotherapy 40 (1), 31-35, 2017 | 119 | 2017 |
| Treatment issues in clear cell carcinoma of the ovary: a different entity? D Pectasides, E Pectasides, A Psyrri, T Economopoulos The oncologist 11 (10), 1089-1094, 2006 | 119 | 2006 |
| Carboplatin and paclitaxel in advanced or metastatic endometrial cancer D Pectasides, N Xiros, G Papaxoinis, E Pectasides, C Sykiotis, ... Gynecologic oncology 109 (2), 250-254, 2008 | 98 | 2008 |
| Systemic therapy in metastatic or recurrent endometrial cancer D Pectasides, E Pectasides, T Economopoulos Cancer treatment reviews 33 (2), 177-190, 2007 | 90 | 2007 |
| Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients ST Kim, KC Banks, E Pectasides, SY Kim, K Kim, RB Lanman, A Talasaz, ... Annals of Oncology 29 (4), 1037-1048, 2018 | 86 | 2018 |
| CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma J Zhou, Z Wu, G Wong, E Pectasides, A Nagaraja, M Stachler, H Zhang, ... Nature communications 8 (1), 13897, 2017 | 78 | 2017 |
| Primary fallopian tube carcinoma: results of a retrospective analysis of 64 patients D Pectasides, E Pectasides, G Papaxoinis, C Andreadis, G Papatsibas, ... Gynecologic Oncology 115 (1), 97-101, 2009 | 76 | 2009 |
| A comprehensive PDX gastric cancer collection captures cancer cell–intrinsic transcriptional MSI traits S Corso, C Isella, SE Bellomo, M Apicella, S Durando, C Migliore, ... Cancer research 79 (22), 5884-5896, 2019 | 71 | 2019 |
| Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis E Pectasides, AM Egloff, C Sasaki, P Kountourakis, B Burtness, ... Clinical Cancer Research 16 (8), 2427-2434, 2010 | 70 | 2010 |
| Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables Y Bai, J Tolles, H Cheng, S Siddiqui, A Gopinath, E Pectasides, RL Camp, ... Laboratory investigation 91 (8), 1253-1261, 2011 | 66 | 2011 |
| Cisplatin-based chemotherapy for Merkel cell carcinoma of the skin D Pectasides, M Pectasides, A Psyrri, A Koumarianou, N Xiros, ... Cancer investigation 24 (8), 780-785, 2006 | 55 | 2006 |
| Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase … HJ Wanebo, J Lee, BA Burtness, JA Ridge, M Ghebremichael, ... Annals of oncology 25 (10), 2036-2041, 2014 | 54 | 2014 |
